Phase II trial of piperazinedione in metastatic sarcoma.
Thirty-five patients with metastatic sarcomas received piperazinedione 9 mg/m2 every 3 weeks. Of 27 evaluable patients, 3 patients had stable disease for at least 6 weeks. The dose-limiting toxicity was myelosuppression. Piperazinedione is inactive in patients with drug-resistant metastatic sarcomas.
D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000627:therapeutic use; D004341:Drug Evaluation; D004351:Drug Resistance; D006801:Humans; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D012509:Sarcoma / Q000188:drug therapy* / Q000556:secondary; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000556:secondary; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors
D000903:Antibiotics, Antineoplastic; D010879:Piperazines; C003905:3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione; D004317:Doxorubicin